Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients.
OR Colegio, A Hanlon, EB Olasz… - Journal of Clinical …, 2013 - europepmc.org
OR Colegio, A Hanlon, EB Olasz, JA Carucci
Journal of Clinical Oncology: Official Journal of the American Society …, 2013•europepmc.orgA comment on this article appears in" Reply to OR Colegio et al." J Clin Oncol. 2013 Sep 10;
31 (26): 3298. This is a comment on" Two-year randomized controlled prospective trial
converting treatment of stable renal transplant recipients with cutaneous invasive squamous
cell carcinomas to sirolimus." J Clin Oncol. 2013 Apr 1; 31 (10): 1317-23.
31 (26): 3298. This is a comment on" Two-year randomized controlled prospective trial
converting treatment of stable renal transplant recipients with cutaneous invasive squamous
cell carcinomas to sirolimus." J Clin Oncol. 2013 Apr 1; 31 (10): 1317-23.
A comment on this article appears in" Reply to OR Colegio et al." J Clin Oncol. 2013 Sep 10; 31 (26): 3298. This is a comment on" Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus." J Clin Oncol. 2013 Apr 1; 31 (10): 1317-23.
europepmc.org